LONDON, Jan 17 (Reuters) - Pharmaceuticals company Shire has agreed to sell its Dermagraft treatment to U.S. group Organogenesis, taking a $650 million hit on the loss-making bio-engineered skin substitute it bought less than three years ago.
Read more here >>
Reuters |
Quails
